Clinical Trials Directory

We are doing this study to find out if a study drug called ivosidenib is a safe and effective option for locally advanced or metastatic conventional chondrosarcoma with an isocitrate dehydrogenase 1 (IDH1) mutation.

In this study, participants will complete two or three in-person visits where they answer surveys and walk for six minutes. After that, they will be placed into one of two groups. One group will start the exercise and nutrition program right away, and the other group will start the program later. The program lasts for twelve weeks. During this time, there will be classes three times each week that last one hour. There will also be a nutrition session every other week. Participants do not need to attend every session, but they are asked to come to at least two thirds of the classes.

We are doing this study to learn more about the connection between the brain and leg muscles in people who have chronic stroke. We want to understand how this connection affects the walking abilities of chronic stroke patients so we can provide better help to stroke patients who need to improve their motor function.

We are doing this study to find out if an experimental drug called PT217 (the study drug) is a safe and effective option for people who have neuroendocrine carcinomas. We want to see how this drug works when it is given on its own and in combination with standard chemotherapy and/or immunotherapy drugs.

We are doing this study to find out if a new type of assessment works well for middle-aged and older adults with sickle cell disease (SCD). We want to see if this assessment is useful in detecting changes in health. We hope the assessment can provide useful information to help improve the quality of life for adults with sickle cell disease.

We are doing this study to find out if an experimental drug called lasofoxifene (the study drug) is a safe and effective option for breast cancer. We want to see if the study drug combined with another drug called abemaciclib has better results than treatment with abemaciclib plus fulvestrant.

We are doing this study to learn more about how different factors in pregnancy lead to healthy babies. Specifically, whether factors related to father's health affect the placenta and baby, what part of placental and fetal genes are related to placenta health and baby growth, and to find out the best time to deliver when the mother has gestational diabetes.

If you can join, you will be placed in Part A or Part B based on when you start. In Part A, you will get one of three study medicines: SPY001, SPY002, or SPY003. In Part B, you will get one of these medicines, a mix of two medicines, or a placebo, which does nothing. The study will last about 97 weeks, and you will have around 20 visits or phone calls. During these, doctors will do tests like blood draws, endoscopy with biopsy, heart checks, and x-rays.